[go: up one dir, main page]

NZ592054A - Dengue virus neutralizing antibodies and uses thereof - Google Patents

Dengue virus neutralizing antibodies and uses thereof

Info

Publication number
NZ592054A
NZ592054A NZ592054A NZ59205409A NZ592054A NZ 592054 A NZ592054 A NZ 592054A NZ 592054 A NZ592054 A NZ 592054A NZ 59205409 A NZ59205409 A NZ 59205409A NZ 592054 A NZ592054 A NZ 592054A
Authority
NZ
New Zealand
Prior art keywords
dengue virus
antibodies
antigen binding
binding fragments
neutralizing antibodies
Prior art date
Application number
NZ592054A
Other languages
English (en)
Inventor
Antonio Lanzavecchia
Original Assignee
Inst Research In Biomedicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Research In Biomedicine filed Critical Inst Research In Biomedicine
Publication of NZ592054A publication Critical patent/NZ592054A/xx

Links

Classifications

    • C07K16/116—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ592054A 2008-10-13 2009-10-13 Dengue virus neutralizing antibodies and uses thereof NZ592054A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10491108P 2008-10-13 2008-10-13
PCT/IB2009/007372 WO2010043977A2 (fr) 2008-10-13 2009-10-13 Anticorps de neutralisation du virus de la dengue et leurs utilisations

Publications (1)

Publication Number Publication Date
NZ592054A true NZ592054A (en) 2013-06-28

Family

ID=42102977

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ592054A NZ592054A (en) 2008-10-13 2009-10-13 Dengue virus neutralizing antibodies and uses thereof

Country Status (10)

Country Link
US (1) US9073981B2 (fr)
EP (1) EP2334700B1 (fr)
JP (2) JP5814790B2 (fr)
CN (2) CN108610416B (fr)
AU (1) AU2009305113B2 (fr)
BR (1) BRPI0914012B1 (fr)
CA (1) CA2739551C (fr)
MX (1) MX2011003588A (fr)
NZ (1) NZ592054A (fr)
WO (1) WO2010043977A2 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2566957T3 (es) 2007-09-26 2016-04-18 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
KR101904232B1 (ko) * 2010-12-14 2018-10-05 내셔널 유니버시티 오브 싱가포르 뎅기 바이러스 세로타입 1 e 프로틴에 특이적인 인간 단일클론 항체 및 그들의 용도
WO2013035345A2 (fr) * 2011-09-09 2013-03-14 Osaka University Anticorps neutralisant les sérotypes du virus de la dengue
US9556254B2 (en) 2012-05-14 2017-01-31 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Cross-reactive antibodies against dengue virus and uses thereof
KR20200102524A (ko) 2012-08-07 2020-08-31 메사추세츠 인스티튜트 오브 테크놀로지 항-뎅기 바이러스 항체 및 이들의 용도
MX2015007575A (es) 2012-12-13 2016-03-15 Univ Pennsylvania Construcciones de anticuerpos de adn y metodo para utilizarlas.
JP7078350B2 (ja) 2013-10-28 2022-05-31 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｄｎａ抗体構築物及びその使用方法
JP6154126B2 (ja) * 2012-12-20 2017-06-28 功 宮崎 検査キットおよび検査方法
MX367668B (es) * 2013-03-15 2019-08-30 Dana Farber Cancer Inst Inc Anticuerpos neutralizadores de flavivirus y métodos de uso de los mismos.
CN103396481B (zh) * 2013-07-18 2015-06-03 华南理工大学 一种二型登革热病毒ns1蛋白的重链单域抗体及其制备方法和应用
EP3080159A4 (fr) * 2013-12-13 2017-08-02 The Trustees Of The University Of Pennsylvania Constructions d'anticorps d'adn et procédé d'utilisation
WO2015095511A2 (fr) * 2013-12-20 2015-06-25 The Scripps Research Institute Anticorps fonctionnels qui modulent la mort cellulaire et procédés associés
WO2015123362A1 (fr) 2014-02-11 2015-08-20 Massachusetts Institute Of Technology Nouveaux anticorps anti-dengue à spectre complet
CA2938590C (fr) 2014-02-11 2023-10-17 Visterra, Inc. Molecules d'anticorps se liant au virus de la dengue et leurs utilisations
HRP20201523T1 (hr) * 2014-09-01 2021-03-05 International Centre For Genetic Engineering And Biotechnology Cjepivo
US11278619B2 (en) 2014-12-01 2022-03-22 The Trustees Of The University Of Pennsylvania DNA antibody constructs and method of using same
CN114773470A (zh) 2015-02-05 2022-07-22 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
JP6957355B2 (ja) * 2015-03-17 2021-11-02 エイジェンシー フォー サイエンス，テクノロジー アンド リサーチ 血清型交差反応性デング熱中和抗体及びその使用
WO2017011495A1 (fr) * 2015-07-14 2017-01-19 Vanderbilt University Anticorps obtenus par génie génétique contre le virus de la dengue
EP3433274A1 (fr) 2016-03-25 2019-01-30 Visterra, Inc. Formulations de molécules d'anticorps contre le virus de la dengue
IL264626B (en) 2016-08-05 2022-07-01 Chugai Pharmaceutical Co Ltd Composition for prophylaxis or treatment of il-8 related diseases
SG10201607778XA (en) * 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
TWI769185B (zh) 2016-10-27 2022-07-01 海樂源有限公司 登革熱類病毒顆粒、抗登革熱病毒抗體、及含其之組合物
WO2018081755A1 (fr) * 2016-10-29 2018-05-03 University Of Miami Anticorps contre le virus zika
US11249082B2 (en) 2016-10-29 2022-02-15 University Of Miami Zika virus assay systems
CN112119090B (zh) 2018-03-15 2023-01-13 中外制药株式会社 对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
KR102238183B1 (ko) 2018-05-04 2021-04-12 가톨릭대학교 산학협력단 유전자 합성을 통해 설계된 뎅기열 바이러스의 유전형 복합 ｎｓ１ 재조합 항원 및 대조군 유행성 플라비바이러스 유전형 복합 ns1 재조합 항원 풀
US11830582B2 (en) 2018-06-14 2023-11-28 University Of Miami Methods of designing novel antibody mimetics for use in detecting antigens and as therapeutic agents
WO2020078568A1 (fr) 2018-10-19 2020-04-23 Humabs Biomed Sa Anticorps et méthodes de traitement de l'infection par le lyssavirus
CN111320688B (zh) * 2018-12-17 2021-08-24 中国科学院天津工业生物技术研究所 一种黄病毒中和抗体、其制备方法及应用
KR102048812B1 (ko) * 2018-12-19 2019-11-26 주식회사 엠디헬스케어 뎅기 바이러스 ediii에 특이적으로 결합하는 dna 압타머 및 이의 용도
WO2021236998A2 (fr) * 2020-05-20 2021-11-25 The Trustees Of Columbia University In The City Of New York Anticorps neutralisants puissants contre le sras-cov-2, leur génération et leurs utilisations

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB819376A (en) 1956-10-20 1959-09-02 Colne Switchgear K & W Ltd Improvements in electro-magnetic overload units for electrical apparatus
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
CU22683A1 (es) * 1997-01-15 2001-07-20 Inst De Medicina Tropical Pedro Kouri Epítopes de la proteína pre-m/m del virus del dengue, péptidos sintéticos, proteínas quiméricas y sus usos
AU8063798A (en) 1997-06-19 1999-01-04 Regents Of The University Of California, The Secretory immunoglobulin produced by single cells and methods for making and using same
WO1999029888A1 (fr) 1997-12-05 1999-06-17 The Scripps Research Institute Humanisation d'anticorps murins
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
EP1600459A3 (fr) 2002-06-28 2005-12-07 Domantis Limited Ligand
US7473424B2 (en) * 2003-01-31 2009-01-06 The Scripps Research Institute Anti-dengue virus antibodies and compositions
WO2004076677A2 (fr) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Production d'anticorps monoclonaux par transformation de lymphocytes b par le virus d'epstein barr
CA2548808C (fr) 2003-12-08 2015-07-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps monoclonaux se liant ou neutralisant le virus de la dengue
JP4782700B2 (ja) 2004-01-20 2011-09-28 カロバイオス ファーマシューティカルズ インコーポレイティッド 最低限必須な結合決定基を用いた抗体特異性の移入
CU23586A1 (es) * 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
EP2144931A2 (fr) * 2007-04-04 2010-01-20 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Anticorps monoclonaux contre le virus de la dengue et d'autres virus avec délétion dans la région fc

Also Published As

Publication number Publication date
JP5814790B2 (ja) 2015-11-17
JP2016020334A (ja) 2016-02-04
CA2739551A1 (fr) 2010-04-22
CA2739551C (fr) 2019-03-05
EP2334700A2 (fr) 2011-06-22
US9073981B2 (en) 2015-07-07
CN108610416B (zh) 2022-01-14
WO2010043977A3 (fr) 2010-09-30
CN102272155B (zh) 2018-05-25
BRPI0914012B1 (pt) 2022-02-15
JP2012504955A (ja) 2012-03-01
AU2009305113A1 (en) 2010-04-22
BRPI0914012A2 (pt) 2021-02-23
CN102272155A (zh) 2011-12-07
AU2009305113B2 (en) 2015-07-16
US20120020957A1 (en) 2012-01-26
MX2011003588A (es) 2011-10-14
EP2334700B1 (fr) 2017-09-13
WO2010043977A2 (fr) 2010-04-22
CN108610416A (zh) 2018-10-02

Similar Documents

Publication Publication Date Title
NZ592054A (en) Dengue virus neutralizing antibodies and uses thereof
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
WO2010017103A3 (fr) Anticorps monoclonaux anti-nkg2d humain entièrement humains
WO2011092593A3 (fr) Anticorps neutralisant le vih-1 et leurs utilisations
EA201291039A1 (ru) Антитела, связывающие cd27 человека, и их применение
WO2010010466A3 (fr) Anticorps neutralisant anti-virus influenza a et leurs utilisations
EA201170205A1 (ru) Антитела, нейтрализующие цитомегаловирус человека, и их применение
MY161200A (en) Human cytomegalovirus neutralising antibodies and use thereof
UA106771C2 (uk) Моноклональні антитіла до прогастрину та їх використання
UA92505C2 (ru) Композиции на основе антитела против cd3
UA106070C2 (uk) Антитіло, що специфічно зв'язується з egfr і her3
WO2010032059A3 (fr) Agents de liaison ciblés dirigés sur cd105 et leurs utilisations
EA201790330A1 (ru) Белки, связывающиеся с bcma (cd269/tnfrsf17)
MX338754B (es) Anticuerpos humanos contra el factor tisular.
WO2009083009A3 (fr) Anticorps monoclonaux anti-cd32b
PH12014502419A1 (en) Specific binding proteins and uses thereof
PH12013502205A1 (en) Antibodies to il-6 and their uses
EA201291243A1 (ru) Антитела против респираторно-синцитиального вируса (рсв) и способы их применения
EA201291067A1 (ru) Гуманизированные антигенсвязывающие белки к миостатину
EA200970874A1 (ru) Антитела против склеростина
NO20090069L (no) Malrettede forbindelser rettet mot binding til PDGFR-alfa og deres anvendelse
EA201291065A1 (ru) Антитела против vla-4
EA201171237A1 (ru) Антитела к dkk-1
MX2010001237A (es) Nuevos anticuerpos.
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 13 OCT 2016 BY CPAPAYMENTS

Effective date: 20131105

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 OCT 2017 BY PAVIS

Effective date: 20160929

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 OCT 2018 BY PAVIS GMBH

Effective date: 20171002

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 OCT 2019 BY PAVIS GMBH

Effective date: 20181010

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 OCT 2020 BY PAVIS GMBH

Effective date: 20190920

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 OCT 2021 BY PAVIS PAYMENTS GMBH

Effective date: 20201008

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 OCT 2022 BY PAVIS PAYMENT GMBH

Effective date: 20211005

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 OCT 2023 BY PAVIS PAYMENT GMBH

Effective date: 20221005

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 OCT 2024 BY PAVIS PAYMENTS GMBH

Effective date: 20230928

LAPS Patent lapsed